Shares of aTyr Pharma, Inc. (LIFE) are rising more than 7% in the morning trade on Wednesday after the company received orphan drug designation from the FDA for its lead drug candidate, efzofitimod, for the treatment of systemic sclerosis.
Orphan drug designation provides certain benefits, including the potential for seven years of market exclusivity following regulatory approval, exemption from FDA application fees and tax credits for qualified clinical trials.
Efzofitimod is a potential first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory disease states via selective modulation of neuropilin-2 (NRP2), the company said.
"We are very pleased to receive orphan drug designation for efzofitimod for SSc, which marks the second such designation for our efzofitimod clinical program," said Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr.
LIFE, currently at $5.06 has traded in the range of $3.50-$13.10 in the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.